Wall Street analysts expect Champions Oncology Inc (NASDAQ:CSBR) to report earnings of ($0.02) per share for the current quarter, Zacks reports. Two analysts have issued estimates for Champions Oncology’s earnings. Champions Oncology posted earnings of $0.03 per share in the same quarter last year, which suggests a negative year-over-year growth rate of 166.7%. The firm is scheduled to report its next quarterly earnings report on Monday, December 16th.
According to Zacks, analysts expect that Champions Oncology will report full-year earnings of $0.01 per share for the current fiscal year. For the next fiscal year, analysts anticipate that the business will post earnings of $0.20 per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Champions Oncology.
Champions Oncology (NASDAQ:CSBR) last announced its earnings results on Monday, September 16th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.03 by ($0.09). The firm had revenue of $6.74 million during the quarter, compared to analyst estimates of $7.50 million. Champions Oncology had a negative net margin of 3.61% and a negative return on equity of 48.07%.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN grew its stake in Champions Oncology by 110.4% in the second quarter. Wells Fargo & Company MN now owns 149,100 shares of the biotechnology company’s stock valued at $1,167,000 after purchasing an additional 78,250 shares in the last quarter. River & Mercantile Asset Management LLP bought a new stake in shares of Champions Oncology during the 2nd quarter worth approximately $1,082,000. BlackRock Inc. raised its stake in shares of Champions Oncology by 12.0% during the 2nd quarter. BlackRock Inc. now owns 137,027 shares of the biotechnology company’s stock worth $1,073,000 after purchasing an additional 14,733 shares in the last quarter. Tocqueville Asset Management L.P. boosted its holdings in shares of Champions Oncology by 69.1% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 134,568 shares of the biotechnology company’s stock valued at $760,000 after buying an additional 55,000 shares during the last quarter. Finally, Alambic Investment Management L.P. boosted its holdings in shares of Champions Oncology by 27.0% in the 2nd quarter. Alambic Investment Management L.P. now owns 68,681 shares of the biotechnology company’s stock valued at $538,000 after buying an additional 14,614 shares during the last quarter. Institutional investors and hedge funds own 49.33% of the company’s stock.
NASDAQ:CSBR traded up $0.31 during trading hours on Thursday, reaching $7.31. 88,395 shares of the stock were exchanged, compared to its average volume of 42,740. Champions Oncology has a twelve month low of $4.98 and a twelve month high of $12.80. The company has a debt-to-equity ratio of 2.06, a current ratio of 0.80 and a quick ratio of 0.80. The firm has a 50 day moving average of $5.68 and a 200 day moving average of $6.75. The stock has a market cap of $84.94 million, a PE ratio of 731.00 and a beta of 1.20.
About Champions Oncology
Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
Featured Story: What is Depreciation?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.